Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biohit Oyj Board/Management Information 2017

May 4, 2017

3304_iss_2017-05-04_6cc6eac8-b7e7-49fe-acba-382352bea774.html

Board/Management Information

Open in viewer

Opens in your device viewer

Disclosure 352055

Biohit Oyj - Changes board/management/auditors

Lea Paloheimo appointed Biohit Oyj’s R&D and production director

Biohit Oyj Changes board/management/ auditors May 4, 2017 at 10:00 a.m. local time (EEST) Lea Paloheimo, PhD (clinical biochemistry), has been appointed Biohit Oyj’s R&D and production director. Lea Paloheimo has been a member of the Biohit Oyj’s management team since 2006. CEO Semi Korpela, Biohit Oyj: ‘Lea Paloheimo has over fifteen years of experience in various positions in Biohit Oyj.’ Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 [email protected] www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com